OTCMKTS:RLMD
Relmada Therapeutics, Inc. Stock News
$3.83
+0.0100 (+0.262%)
At Close: May 08, 2024
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q4 2021 Results - Earnings Call Transcript
08:08pm, Wednesday, 23'rd Mar 2022
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q4 2021 Results - Earnings Call Transcript
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022
08:30am, Wednesday, 16'th Mar 2022
CORAL GABLES, Fla., March 16, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc
Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential
11:42am, Wednesday, 23'rd Feb 2022
Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor
Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
01:30pm, Thursday, 10'th Feb 2022 PR Newswire
CORAL GABLES, Fla., Feb. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial
4 Clinical Catalysts On Tap For Relmada In 2022
01:06pm, Friday, 28'th Jan 2022
RLMD is set to produce results in 2022 from four clinical trials of REL-1017, its novel antidepressant. Late-stage failures of antidepressants are not unheard of, so I provide a cautionary tale to RLM
Wall Street Analysts See a 231% Upside in Relmada Therapeutics, Inc. (RLMD): Can the Stock Really Move This High?
11:31am, Wednesday, 12'th Jan 2022
The mean of analysts' price targets for Relmada Therapeutics, Inc. (RLMD) points to a 231.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agre
5 Sizzling ‘Strong Buy' Analyst Biotechnology Picks for 2022
07:15am, Tuesday, 04'th Jan 2022
For years, one of the most dependable sectors, especially for investors who are more conservative, was health care.
Data - Relmada Therapeutics Price Target Lowered to $42.00 at SVB Leerink
06:51am, Thursday, 23'rd Dec 2021 Business Mag
Relmada Therapeutics had its price objective decreased by SVB Leerink from $50.00 to $42.00 in a research report sent to investors on Monday morning, PriceTargets.com reports…
Brokerages Expect Relmada Therapeutics, Inc. (NASDAQ:RLMD) to Post -$1.87 EPS
09:48pm, Saturday, 18'th Dec 2021 Dakota Financial News
Equities analysts forecast that Relmada Therapeutics, Inc. (NASDAQ:RLMD) will post earnings per share (EPS) of ($1.87) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Relmada Therapeutics earnings. The lowest EPS estimate is ($1.96) and the highest is ($1.79). Relmada Therapeutics reported earnings per share of ($1.28) in the []
-$1.87 Earnings Per Share Expected for Relmada Therapeutics, Inc. (NASDAQ:RLMD) This Quarter
11:20am, Tuesday, 14'th Dec 2021 Transcript Daily
Wall Street analysts expect Relmada Therapeutics, Inc. (NASDAQ:RLMD) to report earnings per share of ($1.87) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Relmada Therapeutics earnings, with the highest EPS estimate coming in at ($1.79) and the lowest estimate coming in at ($1.96). Relmada Therapeutics reported earnings []
Relmada Therapeutics raises $150M through stock offering
10:40am, Thursday, 09'th Dec 2021 Seeking AlphaRelmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate
07:23am, Thursday, 09'th Dec 2021
Relmada Therapeutics Inc (NASDAQ: RLMD) priced an upsized underwritten public offering of 8.82 million shares at $17.00 per share, with gross proceeds of approximately $150 million. The offer pric
Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
04:21am, Thursday, 09'th Dec 2021 PR Newswire
CORAL GABLES, Fla., Dec. 8, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common
Relmada Therapeutics slides on $100M common stock offering
09:29pm, Wednesday, 08'th Dec 2021 Seeking AlphaRelmada Therapeutics Announces Proposed Public Offering of Common Stock
09:19pm, Wednesday, 08'th Dec 2021 Intrado Digital Media
CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced its intention to offer and sell $100 million of shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.